These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 17786395)

  • 21. Fibrosis and immune dysregulation in systemic sclerosis.
    Chizzolini C; Brembilla NC; Montanari E; Truchetet ME
    Autoimmun Rev; 2011 Mar; 10(5):276-81. PubMed ID: 20863906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of PDGF in fibrotic diseases and systemic sclerosis.
    Trojanowska M
    Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v2-4. PubMed ID: 18784131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transforming growth factor-beta 1 and collagen gene expression during postnatal skin development and fibrosis in the tight-skin mouse.
    Pablos JL; Everett ET; Harley R; LeRoy EC; Norris JS
    Lab Invest; 1995 Jun; 72(6):670-8. PubMed ID: 7783425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma.
    Sonnylal S; Denton CP; Zheng B; Keene DR; He R; Adams HP; Vanpelt CS; Geng YJ; Deng JM; Behringer RR; de Crombrugghe B
    Arthritis Rheum; 2007 Jan; 56(1):334-44. PubMed ID: 17195237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Animal models of scleroderma: lessons from transgenic and knockout mice.
    Derrett-Smith EC; Denton CP; Sonnylal S
    Curr Opin Rheumatol; 2009 Nov; 21(6):630-5. PubMed ID: 19730378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transforming growth factor-beta in systemic sclerosis (scleroderma).
    Varga J; Whitfield ML
    Front Biosci (Schol Ed); 2009 Jun; 1(1):226-35. PubMed ID: 19482698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heparan sulfate-dependent ERK activation contributes to the overexpression of fibrotic proteins and enhanced contraction by scleroderma fibroblasts.
    Chen Y; Leask A; Abraham DJ; Pala D; Shiwen X; Khan K; Liu S; Carter DE; Wilcox-Adelman S; Goetinck P; Denton CP; Black CM; Pitsillides AA; Sarraf CE; Eastwood M
    Arthritis Rheum; 2008 Feb; 58(2):577-85. PubMed ID: 18240216
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis.
    Maurer B; Distler A; Suliman YA; Gay RE; Michel BA; Gay S; Distler JH; Distler O
    Ann Rheum Dis; 2014 Oct; 73(10):1880-7. PubMed ID: 23918036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of dermal connective tissue in scleroderma.
    Kähäri VM
    Ann Med; 1993 Dec; 25(6):511-8. PubMed ID: 8292298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The transcription factor JunD mediates transforming growth factor {beta}-induced fibroblast activation and fibrosis in systemic sclerosis.
    Palumbo K; Zerr P; Tomcik M; Vollath S; Dees C; Akhmetshina A; Avouac J; Yaniv M; Distler O; Schett G; Distler JH
    Ann Rheum Dis; 2011 Jul; 70(7):1320-6. PubMed ID: 21515915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Platelet-derived growth factor-BB and transforming growth factor beta 1 selectively modulate glycosaminoglycans, collagen, and myofibroblasts in excisional wounds.
    Pierce GF; Vande Berg J; Rudolph R; Tarpley J; Mustoe TA
    Am J Pathol; 1991 Mar; 138(3):629-46. PubMed ID: 2000940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TGF beta--a role in systemic sclerosis?
    Cotton SA; Herrick AL; Jayson MI; Freemont AJ
    J Pathol; 1998 Jan; 184(1):4-6. PubMed ID: 9582519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of apoptosis and transforming growth factor beta1 in fibroblast selection and activation in systemic sclerosis.
    Jelaska A; Korn JH
    Arthritis Rheum; 2000 Oct; 43(10):2230-9. PubMed ID: 11037882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulation of PDGF and its receptors in fibrotic diseases.
    Bonner JC
    Cytokine Growth Factor Rev; 2004 Aug; 15(4):255-73. PubMed ID: 15207816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Scleroderma, dermatomyositis].
    Yamakage A
    Nihon Rinsho; 1994 Aug; 52(8):2114-9. PubMed ID: 7933595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sustained activation of fibroblast transforming growth factor-beta/Smad signaling in a murine model of scleroderma.
    Takagawa S; Lakos G; Mori Y; Yamamoto T; Nishioka K; Varga J
    J Invest Dermatol; 2003 Jul; 121(1):41-50. PubMed ID: 12839562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Animal models of systemic sclerosis: insights into systemic sclerosis pathogenesis and potential therapeutic approaches.
    Christner PJ; Jimenez SA
    Curr Opin Rheumatol; 2004 Nov; 16(6):746-52. PubMed ID: 15577614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pathogenesis of skin scleroderma--literature review].
    Wojas-Pelc A; Lipko-Godlewska S
    Przegl Lek; 2005; 62(5):310-3. PubMed ID: 16334538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis.
    Baroni SS; Santillo M; Bevilacqua F; Luchetti M; Spadoni T; Mancini M; Fraticelli P; Sambo P; Funaro A; Kazlauskas A; Avvedimento EV; Gabrielli A
    N Engl J Med; 2006 Jun; 354(25):2667-76. PubMed ID: 16790699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cellular and molecular mechanisms of bleomycin-induced murine scleroderma: current update and future perspective.
    Yamamoto T; Nishioka K
    Exp Dermatol; 2005 Feb; 14(2):81-95. PubMed ID: 15679577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.